• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Hematology

Latest News

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com
Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Patients with an inflammatory transcriptome profile at 3 months had a greater risk of an infection. | Image credit: Saiful52 - stock.adobe.com
Immune Profiling May Help Gauge Infection Risk in Patients With CLL

August 31st 2025

Adults and adolescents with sickle cell disease experienced early, sustained, and clinically meaningful improvements in HRQOL measures following exa-cel infusion. | Image credit: Ezume Images - stock.adobe.com
Gene Therapy Meaningfully Improves Quality of Life in Severe Sickle Cell Disease

August 29th 2025

Real-world outcomes of venetoclax treatment were similar to those seen in clinical trials in patients with chronic lymphocytic leukemia | Image Credit: tippapatt - stock.adobe.com
Real-World Data Support Safety, Efficacy of Venetoclax for CLL

August 29th 2025

It was difficult to generate strong conclusions from the existing data due to the “sparse and heterogeneous” nature of the cardiovascular data reported in the trials. | Image credit: Tima - stock.adobe.com
Age, BTKi Use May Contribute to Cardiovascular Risk in CLL

August 27th 2025

<1
...
2526272829
© 2025 MJH Life Sciences
AJMC®
All rights reserved.